Quigley has launched over-the-counter Kids-EEZE Chest Relief, a chewable expectorant for the relief of cough and chest congestion in children ≥6 years of age.
Bayer’s Kogenate FS (recombinant antihemophilic Factor VIII) has been approved for the prophylaxis of hemophilia A in children 0-16 years of age without pre-existing joint damage.
Cinryze (C1 inhibitor [human], from Lev Pharmaceuticals) has been approved for routine prophylaxis against angioedema attacks in hereditary angioedema (HAE), also known as C1 inhibitor deficiency.
AstraZeneca’s Seroquel XR (quetiapine fumarate extended-release tablets) has been approved for the treatment of depressive episodes in bipolar disorder, manic and mixed episodes in bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex.
The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia.
Manufacturers of over-the-counter (OTC) children’s cough and cold medicines are voluntarily changing their labels to advise parents not to use in children <4 years of age and not to use antihistamines to sedate children.